|1.||Iversen, Peter: 14 articles (07/2015 - 08/2002)|
|2.||Gravina, Giovanni Luca: 10 articles (12/2011 - 09/2002)|
|3.||Festuccia, Claudio: 10 articles (12/2011 - 09/2002)|
|4.||See, William A: 10 articles (04/2010 - 08/2002)|
|5.||McLeod, David G: 8 articles (04/2010 - 08/2002)|
|6.||Wirth, Manfred P: 8 articles (04/2010 - 08/2002)|
|7.||Bologna, Mauro: 8 articles (08/2009 - 09/2002)|
|8.||Vicentini, Carlo: 8 articles (08/2009 - 09/2002)|
|9.||Tammela, Teuvo L J: 7 articles (07/2015 - 08/2002)|
|10.||Wirth, M: 7 articles (01/2007 - 01/2001)|
|1.||Prostatic Neoplasms (Prostate Cancer)
06/01/2012 - "On different prostate cancer cell lines MEL-3 displayed an improved therapeutic profile compared with bicalutamide. "
01/01/1989 - "Following promising results in animal studies, Casodex (ICI 176,334) has been studied in the treatment of patients with advanced prostate cancer. "
04/01/2005 - "Compared to bicalutamide, YM-175735 is an approximately 4-fold stronger AR antagonist and has slightly increased antiandrogenic activity, suggesting that YM-175735 may be useful in the treatment of prostate cancer."
05/01/2014 - "Efficacy of Bicalutamide 150-mg Monotherapy Compared With Combined Androgen Blockade in Patients With Locally Advanced Prostate Cancer."
04/01/2010 - "Bicalutamide 150 mg, either as monotherapy or adjuvant to standard care, improved PFS in patients with locally advanced prostate cancer, but not in patients with localized disease. "
06/01/2015 - "First-generation compounds such as bicalutamide had modest efficacy, and in the setting of AR overexpression or specific mutations in the AR ligand-binding domain, these early compounds had partial agonist properties that could stimulate tumor growth. "
04/01/2015 - "CH5137291 inhibited the growth of LNCaP tumors that had become resistant to bicalutamide treatment. "
01/01/2014 - "Nevertheless, bicalutamide treatment of intra-femoral tumors significantly reduced PSA expression (p < = 0.008) and increased AR (p < = 0.032) relative to control. "
01/01/2014 - "However, bicalutamide was ineffective in suppressing PCSD1 tumor growth in the bone-niche. "
11/01/2013 - "These effects were overcome by the combination of AZD5363 with the antiandrogen bicalutamide, resulting in synergistic inhibition of cell proliferation and induction of apoptosis in vitro, and prolongation of tumor growth inhibition and PSA stabilization in CRPC in vivo. "
04/01/2010 - "The overall tolerability of bicalutamide was consistent with previous analyses, with breast pain (73.7%) and gynaecomastia (68.8%) the most frequently reported adverse events in patients randomized to bicalutamide. "
05/01/2005 - "Gynaecomastia and breast pain are frequent adverse events with bicalutamide monotherapy, and might cause some patients to withdraw from treatment. "
06/01/2003 - "The adverse effects most frequently reported in the bicalutamide group were gynaecomastia and breast pain. "
12/01/2002 - "Although better tolerated, bicalutamide has significant problems with gynaecomastia and breast pain. "
07/01/2001 - "There was evidence of palliation with three measures of pain and, to a lesser extent, with a measure of overall symptom status after 3 months of taking bicalutamide. "
08/01/2012 - "We undertook a meta-analysis to assess the efficacy of various treatment options for bicalutamide-induced gynecomastia. "
08/01/2012 - "The medline, cancerlit, and Cochrane library databases were searched and the Google search engine was used to identify prospective and retrospective controlled studies published in English from January 2000 to December 2010 comparing prophylactic or curative treatment options with a control group (no treatment) for pca patients who developed bicalutamide-induced gynecomastia. "
08/01/2010 - "Although prophylactic breast irradiation seemed to decrease the gynecomastia rate in patients on 150 mg bicalutamide, our study proves that not all patients need prophylaxis since only 52% were significantly bothered by gynecomastia. "
01/01/2015 - "To systematically review the quality of evidence of the current literature regarding treatment options for bicalutamide-induced gynecomastia, including efficacy, safety and patients' quality of life. "
08/01/2012 - "Optimal prophylactic and definitive therapy for bicalutamide-induced gynecomastia: results of a meta-analysis."
09/01/2007 - "Complete remission of metastatic carcinoma of the prostate with bicalutamide withdrawal."
03/01/2002 - "[Efficacy of bicalutamide in adjuvant treatment of prostatic carcinoma after primary therapy with curative aim. "
01/01/2005 - "Bicalutamide is a non-steroidal anti-androgen commonly used in the treatment of prostate carcinoma. "
09/01/2002 - "Bicalutamide dose-dependently inhibits proliferation in human prostatic carcinoma cell lines and primary cultures."
02/01/1998 - "On the other hand, when visible carcinomas and microscopic carcinomas were handled together, only casodex 60 mg/kg significantly inhibited the carcinogenesis rate. "
|1.||Gonadotropin-Releasing Hormone (GnRH)
|5.||acetyl- 2- naphthylalanyl- 3- chlorophenylalanyl- 1- oxohexadecyl- seryl- 4- aminophenylalanyl(hydroorotyl)- 4- aminophenylalanyl(carbamoyl)- leucyl- ILys- prolyl- alaninamide
|10.||Androgen Antagonists (Antiandrogens)
|3.||Heterologous Transplantation (Xenotransplantation)
|4.||Prostatectomy (Retropubic Prostatectomy)